Cellares
Chemicals & Related Products · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
345 Allerton Ave, South San Francisco, C...Phone Number
(833) 235-5273Website
www.cellares.comRevenue
$94.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
4
1
1
1
1
About Cellares
Cellares is an Integrated Development and Manufacturing Organization (IDMO) focused on the automated, large-scale manufacture of cell therapies. The company provides global biopharmaceutical partners with development and commercial manufacturing services designed to address the capacity, consistency, and cost limitations of traditional, labor-intensive production models. Cellares operates fully automated manufacturing and quality control platforms Cell Shuttle for end-to-end cell therapy manufacturing and Cell Q for automated in-process and release testing across its network of IDMO Smart Factories. These cGMP-compliant systems enable higher process reproducibility, improved manufacturing success rates, and up to approximately 10 higher throughput compared to conventional CDMO approaches with similar footprint and headcount. Headquartered in South San Francisco, California, Cellares operates a commercial-scale Smart Factory in Bridgewater, New Jersey, with additional facilities under cRead more
Cellares Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cellares your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Cellares
Click to see if Cellares had a recent Job posting/layoffs
Check out if Cellares is spiking on competitors!
Earning: See what the market has to say on Cellares recently announced quarterly report
Check if Cellares has recently received funding, and reach out quickly before it becomes old news!
Cellares, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Cellares launches new products
Funding: Get notified immidiatlly once Cellares has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Cellares
Find 3 more new buyers
Compare Similar Companies to Cellares
Compare insights from companies similar to Cellares, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cellares is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cellares is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cellares.
Cellares financials insights
Gather financial insights about Cellares, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$18M
2021
Series B
$82M
2023
Series C
$255M
2026
Series D
$257M
Series D
$50M
Cellares Tech Stack
A closer look at the technologies used by Cellares
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Hiring Plans
Hiring Plans
Cellares News & Media
Cathie Wood's ARK Invest Joins Cellares' $277 Million Series D | Business - Rutland Herald
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun 9, 2026--Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many thousands of patients per year at a cost per batch that is among the lowest in the industryBlackRock, Eclipse Lead Cellares' $257M Funding Round - Law360
Integrated development and manufacturing organization company Cellares, which focuses on the large-scale manufacturing of cell therapies, on Wednesday announced that it closed a $257 million funding round, bringing the South San Francisco, California-based company's total capital raised to $612 million.Cellares Raises $257 Million Series D Led by BlackRock and Eclipse to Industrialize Global ...
SOUTH SAN FRANCISCO, Calif., January 28, 2026--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced a $257 million Series D financing co‑led by investment funds managed by BlackRock and Eclipse, bringing the company’s total capital raised to $612 million.
Read more news
Top Chemicals & Related Products Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cellares
Sign Up For FreeTo access detailed company insights
Cellares is an Integrated Development and Manufacturing Organization (IDMO) focused on the automated, large-scale manufacture of cell therapies. The company provides global biopharmaceutical partners with development and commercial manufacturing services designed to address the capacity, consistency, and cost limitations of traditional, labor-inten... Read More
